{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cytotoxic+t-lymphocytes&page=3", "query": { "intervention": "cytotoxic t-lymphocytes", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 320, "total_pages": 32, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cytotoxic+t-lymphocytes&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cytotoxic+t-lymphocytes&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T08:50:57.408Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06581406", "title": "A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "RP2", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 280, "start_date": "2024-12-17", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-08T08:50:57.408Z", "location_count": 29, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06581406" }, { "nct_id": "NCT01144247", "title": "Cellular Immunotherapy Study for Brain Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gliomas", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Anaplastic Mixed Glioma", "Glioblastoma Multiforme", "Malignant Meningioma" ], "interventions": [ { "name": "alloreactive CTL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2010-07", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2016-05-27", "last_synced_at": "2026-10-08T08:50:57.408Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01144247" }, { "nct_id": "NCT02510404", "title": "Multivirus-specific Cytotoxic T Lymphocytes (mCTL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Viral Infections" ], "interventions": [ { "name": "mCTLs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Catherine Bollard", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": "45 Years", "sex": "ALL", "summary": "4 Weeks to 45 Years" }, "enrollment_count": 1, "start_date": "2014-04", "completion_date": "2019-06-08", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-08T08:50:57.408Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02510404" }, { "nct_id": "NCT03600155", "title": "Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Allogeneic Hematopoietic Stem Cell Transplantation Recipient", "Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2018-10-11", "completion_date": "2024-12-02", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-08T08:50:57.408Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03600155" }, { "nct_id": "NCT02771626", "title": "Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma (ccRCC)", "Melanoma", "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2016-08-01", "completion_date": "2020-04-24", "has_results": true, "last_update_posted_date": "2023-03-17", "last_synced_at": "2026-10-08T08:50:57.408Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Athens", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02771626" }, { "nct_id": "NCT04084951", "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Tumor" ], "interventions": [ { "name": "SQZ-PBMC-HPV", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SQZ Biotechnologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-01-28", "completion_date": "2023-02-09", "has_results": false, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-10-08T08:50:57.408Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04084951" }, { "nct_id": "NCT01239368", "title": "Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloma, Plasma-Cell", "Myeloma-Multiple", "Myelomatosis" ], "interventions": [ { "name": "Adoptive Immunotherapy", "type": "PROCEDURE" }, { "name": "Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)", "type": "BIOLOGICAL" }, { "name": "Th1/Tc1 Rapa Cell Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 34, "start_date": "2010-11-10", "completion_date": "2017-08-16", "has_results": true, "last_update_posted_date": "2019-12-10", "last_synced_at": "2026-10-08T08:50:57.408Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Hackensack, New Jersey", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01239368" }, { "nct_id": "NCT02339571", "title": "A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Stage III Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Elastography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2015-11-23", "completion_date": "2033-06-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-08T08:50:57.408Z", "location_count": 763, "location_summary": "Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 494 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02339571" }, { "nct_id": "NCT05896839", "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8", "Metastatic Basal Cell Carcinoma", "Metastatic Carcinoma in the Skin", "Metastatic Melanoma", "Metastatic Merkel Cell Carcinoma", "Metastatic Skin Squamous Cell Carcinoma", "Unresectable Basal Cell Carcinoma", "Unresectable Melanoma", "Unresectable Merkel Cell Carcinoma", "Unresectable Skin Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Kidney Biopsy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2024-07-24", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-08T08:50:57.408Z", "location_count": 26, "location_summary": "La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 18 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05896839" }, { "nct_id": "NCT07155317", "title": "Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Acral Melanoma", "Advanced Cutaneous Melanoma", "Advanced Mucosal Melanoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Acral Melanoma", "Metastatic Cutaneous Melanoma", "Metastatic Mucosal Melanoma", "Unresectable Acral Melanoma", "Unresectable Cutaneous Melanoma", "Unresectable Mucosal Melanoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2025-10-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-08T08:50:57.408Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07155317" } ] }